论文部分内容阅读
目的:观察希罗达对晚期胃癌和乳腺癌的疗效和毒副反应。方法:采用希罗达治疗42例晚期胃癌或乳腺癌患者,希罗达剂量为2500mg/(m2·d),分两次口服,d1～d14,每3周为1个周期,至少化疗2个周期后评价疗效,(CR+PR)为有效。结果:42例患者全部可评价疗效,其中CR2例,PR8例。总有效率(CR+PR)为23.8%。患者中位疾病进展时间为6.5个月。主要毒性作用为手足综合征,其他有恶心呕吐、皮肤色素沉着、腹泻。结论:希罗达对晚期胃癌和乳腺癌疗效好,毒副反应小。
Objective: To observe the efficacy and toxicity of Xeloda on advanced gastric cancer and breast cancer. Methods: Forty-two patients with advanced gastric cancer or breast cancer were treated with Xeloda. The dose of Xeloda was 2500 mg / (m2 · d) orally. The dosage of Xeloda was orally administered twice daily for 1 d, Evaluation of efficacy after the cycle, (CR + PR) is valid. Results: All 42 patients could evaluate the curative effect, including CR2 cases and PR8 cases. The total effective rate (CR + PR) was 23.8%. The median time to progression was 6.5 months. The main toxic effects of hand-foot syndrome, others have nausea and vomiting, skin pigmentation, diarrhea. Conclusion: Xeloda has a good curative effect on advanced gastric cancer and breast cancer with little toxic and side effects.